anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Acute exacerbation is the first leading cause of hospitalization and mortality among patients with COPD. Infection of bacteria has been detected in 49.59% of patients with AECOPD. Antibiotic prescriptions for AECOPD patients are usually based on GOLD guideline. However, the newest study reported that more than 85% of AECOPD inpatients received antibiotic prescription in the United States, Europe and China. Not all patients will equally experience benefit from antibiotics. Interleukin 6 (IL6) was determined as a reliable clinical biomarker in guiding antimicrobial use. It remains unclear whether IL6-guided antibiotic therapy is safe and effective for hospitalized patients with AECOPD.

The study will recruit 440 AECOPD inpatients from at least six hospitals based in China. Eligible participants will be assigned to receive either IL6-guided antibiotic therapy or GOLD-guided antibiotic therapy in 1:1 ratio randomly. The hypothesis for this study is that IL-6 guided antibiotic therapy will reduce the rate of antibiotic prescriptions for AECOPD without increasing the rate of treatment failure, compared with the group treated with GOLD-guided antibiotic therapy.
Ginger, a well-known spice plant, has been used widely in medicinal preparations for pain relief. However, little is known about its analgesic components and the underlying mechanism. Here, we ascertained, the efficacy of ginger ingredient 8-Shogaol (8S), on inflammatory pain and tolerance induced by morphine, and probed the role of TRPV1 in its analgesic action using genetic and electrophysiology approaches. Results showed that 8S effectively reduced nociceptive behaviors of mice elicited by chemical stimuli, noxious heat as well as inflammation, and antagonized morphine analgesic tolerance independent on opioid receptor function. Genetic deletion of TRPV1 significantly abolished 8S' analgesia action. Further calcium imaging and patch-clamp recording showed that 8S could specifically activate TRPV1 in TRPV1-expressing HEK293T cells and dorsal root ganglion (DRG) neurons. The increase of [Ca2+]i in DRG was primarily mediated through TRPV1. Mutational and computation studies revealed the key binding sites for the interactions between 8S and TRPV1 included Leu515, Leu670, Ile573, Phe587, Tyr511, and Phe591. Further studies showed that TRPV1 activation evoked by 8S resulted in channel desensitization both in vitro and in vivo, as may be attributed to TRPV1 degradation or TRPV1 withdrawal from the cell surface. Collectively, this work provides the first evidence for the attractive analgesia of 8S in inflammatory pain and morphine analgesic tolerance mediated by targeting pain-sensing TRPV1 channel. 8S from dietary ginger has potential as a candidate drug for the treatment of inflammatory pain.
Application of TIMP-1 in preparing medicine for preventing and treating traumatic brain injury. The invention discloses an application of TIMP-1 in preparing a medicament for treating traumatic brain injury blood brain barrier dysfunction, wherein the medicament can be in the form of powder injection, aqueous solution, liposome and nano material. The TIMP-1 protein can improve the latency period of a bar-rotating experiment of a mouse with brain trauma; improving the exercise balance ability of the mice with the brain trauma on the balance beam; decreasing evans blue permeability of brain tissue. In the brain microvascular endothelial cell HBMEC, TIMP-1 can participate in maintaining the integrity of intercellular tight junctions, up-regulate the expression of tight junction complexes, reduce luciferase leakage and increase intercellular resistance. The invention also provides application of the TIMP-1 protein as a CD63-Integrin beta 1 ligand in preparing a medicament for treating central nervous system diseases caused by blood brain barrier disorder, wherein the TIMP-1 needs to be combined with a cell membrane complex CD63-Integrin beta 1 to play a role, regulate and control the assembly of important molecules F-actin of a cytoskeleton and further maintain the tight connection integrity between cells. The TIMP-1 protein has good application prospect in treating traumatic brain injury blood brain barrier dysfunction.
The present invention relates to an effervescence tablet of miconazole nitrate for vagina. According to parts by weight, the present invention contains 200 parts of miconazole nitrate, 150 to 160 parts of tartaric acid, 165 to 175 parts of sodium bicarbonate, 120 to 130 parts of microcrystalline cellulose, 804 to 6 parts of polysorbate, 25 to 30 parts of sodium carboxymethyl starch and 12 to 16 parts of magnesium stearate. The present invention is medicine which is suitable for the woman's vagina. The medicine can be disintegrated in a short time, effective components of the medicine are uniformly released and dissolved along with foam, a patient can easily accept the medicine, the medicine is suitable for being clinically popularized and used, and the medicine action can be quickly exerted. The present invention has the advantages of stable quality of products, simple preparation technology and controllable quality. The present invention is suitable for industrialization mass preparation and is suitable for being clinically popularized and used. Patients' requirements are satisfied.
The Mindfulness Training Instructor Administered ("MTIA") intervention will incorporate the following elements: training in an 8-week, 90-minute per week, modified mindfulness program, which places additional emphasis on training which is feasible and relevant to race/ethnic groups, including: a) didactics on relevance to stress, coping and resilience, b) mindful compassion for self and others; c) mindful communication, including non-verbal mindfulness, mindful listening, and mindful speaking. The MTIA will be instructor led, internet-delivered (via Zoom), interactive, group-based mindfulness training intervention that will incorporate the training for approximately 9 persons in a group format, with outside-of session assignments.
Fetal/Neonatal Adverse Reactions \- Prolonged use of opioid analgesics during pregnancy for medical or nonmedical purposes can result in physical dependence in the neonate and neonatal opioid withdrawal syndrome shortly after birth. 

Neonatal opioid withdrawal syndrome presents as irritability, hyperactivity and abnormal sleep pattern, high pitched cry, tremor, vomiting, diarrhea and failure to gain weight. The onset, duration, and severity of neonatal opioid withdrawal syndrome vary based on the specific opioid used, duration of use, timing and amount of last maternal use, and rate of elimination of the drug by the newborn. Observe newborns for symptoms of neonatal opioid withdrawal syndrome and manage accordingly [see WARNINGS]. 

Labor or Delivery \- Opioids cross the placenta and may produce respiratory depression and psycho-physiologic effects in neonates. An opioid antagonist, such as naloxone, must be available for reversal of opioid-induced respiratory depression in the neonate. Acetaminophen and codeine phosphate tablets are not recommended for use in pregnant women during or immediately prior to labor, when other analgesic techniques are more appropriate. Opioid analgesics, including acetaminophen and codeine phosphate tablets, can prolong labor through actions which temporarily reduce the strength, duration, and frequency of uterine contractions. However, this effect is not consistent and may be offset by an increased rate of cervical dilation, which tends to shorten labor. Monitor neonates exposed to opioid analgesics during labor for signs of excess sedation and respiratory depression. 

Narcotic analgesics should be avoided during labor if delivery of a premature infant is anticipated. If the mother has received narcotic analgesics during labor, newborn infants should be observed closely for signs of respiratory depression. Resuscitation may be required [see OVERDOSAGE]. The effect of codeine, if any, on the later growth, development, and functional maturation of the child is unknown.
Long-term studies in animals have not been performed to evaluate carcinogenic potential of VARITHENA. No mutagenic activity was observed in the in vitro bacterial reverse mutation assay at non-toxic concentrations. No mutagenic activity was observed in the in vitro mouse lymphoma assay in the absence of S9 mix and was weakly mutagenic in the presence of S9 close to the limit of acceptance for the accompanying level of toxicity. No micronucleus induction was detected in the in vivo assay on mouse bone marrow cells up to the maximum tolerated dose of 80 mg/kg. 

There was no adverse effect on fertility in both male and female rats at 27 mg/kg/day. This dose level is approximately 13.5 times the proposed maximum human dose based on body surface area.
Assessments will be administered via telephone by a research assistant blind to group assignment. Participants will complete outcome assessments upon enrollment (T1) and at 8 weeks (T2), 20 weeks (T3) and 44 weeks (T4) later. The T2 assessment captures the short-term outcomes of the most intensive part of the intervention (i.e., after six weekly sessions). The T3 assessment will capture the short-term outcomes at the end of the full intervention. The T4 assessment explores the sustained effect of BA/PS (six months after BA/PS ends). The study aim is to test whether the BA/PS intervention affects the "slope" of functional recovery over time. With the longitudinal data, the investigators will also be able to explore the pace of improvement and whether the two groups differ at these clinically relevant time points.
FIELD: medicine, particularly, biologically active substances of natural origin. SUBSTANCE: preparation is an aqueous-alcoholic extraction from 24 species of medicinal raw material with preset ratio of components. For production of final product, added to the aqueous-alcoholic extraction are apple juice, natural honey, caramel color, ethyl alcohol and water in the following ratio: aqueous-alcoholic extraction from vegetable raw material, 250-300 ml; apple juice, 15-25 ml; natural honey, 40-50 g; caramel color, 50-10; alcohol, 200-300 ml; cleaned water, up to 1000 ml. The preparation is recommended for patients with asthenic state, intellectual and physical overwork, neurosis, and also for treatment of patients suffered from serious infectious diseases or in their postoperative period. EFFECT: stable therapeutic action. 1 cl
Anorectal malformations (ARMs) consist of a range of anomalies that are often associated with other anomalies The purpose of the study is to assess the incidence of associated congenital anomalies that are seen in patients with ARMs. An observational prospective study was conducted on 162 cases with ARM from February 2019 to January 2020, and data were collected on patient demographics, type of ARM, and associated anomalies using a prestructured questionnaire and analysis done using SPSS (IBM), version 23, software. Relevant statistical analysis was done, and the results are presented in tables and charts. Of 162 cases studied, 70 of them were males and 92 were females with a male-to-female ratio of 0.76:1. The majority of male patients (45%) had rectourethral fistulas, whereas 63% of the females had rectovestibular fistula. While 76 (47%) patients presented with isolated ARM, 86 (53%) had ≥1 associated congenital malformations. Forty-eight (30%) patients presented with a single associated anomaly, whereas 20 (12%) patients had≥3 associated anomalies. The commonest associated anomalies were urologic 26.5% followed by genital (22.8%), cardiac 20.4%, and musculoskeletal 16.6%, and 12.3% of them had vertebral; anorectal; cardiac; tracheoesophageal fistula; renal; limb association. More than half of the children have other associated abnormalities. We found urogenital anomalies to be the most common associated congenital defects. A lower incidence of cardiac and spinal cord anomalies was noted suggesting a need for active workup to be in line with the latest standards of care.
CNSI (50 mg/dose) was produced by Chongqing Lesmei Pharmaceutical Co., Ltd.: Carbon nanoparticles were marked in the endoscopy division 1 day before surgery, and CNSI was injected submucosally at 4 points (proximal side, distal side, and left and right sides) 0.5-1 cm from the tumor edge under endoscopy. The test dose for each point was approximately 0.25 ml.
Total Knee Arthroplasty (TKA) is a surgery that is commonly performed on older adults to improve their quality of life. However, the increasing use of knee joint prostheses has led to a rise in the incidence of Prosthetic Joint Infections (PJI) in patients after TKA. Different clinical studies have looked at the occurrence of PJI after TKA in different regions, but they have drawn varying conclusions. To better understand this topic, we conducted a meta-analysis and bibliometric study using data from multiple databases. Our research found that the estimated prevalence of PJI after TKA is approximately 1.08% across different regions, but there is still considerable variation. Additionally, our regression analysis of sub-groups shows significant differences in follow-up periods. Furthermore, our comprehensive bibliometric analysis identifies current research trends, "hotspots" related to TKA-related PJI, influential nations, organizations, and noteworthy publications. Our analysis provides valuable insights to guide future research in this area.
Patients undergo standard face-to-face follow up visits as in Group I. Patients also undergo mobile surveillance comprising use of a mobile device application to send photos and videos to study staff and engage in video conferences at 3, 7, 13, and 25 weeks after surgery.
OBJECTIVES: I. Compare survival in patients with malignant pleural mesothelioma when treated with cisplatin with or without LY231514. II. Compare duration of response, time to progression, and time to treatment failure in these patients with these treatment regimens. III. Compare tumor response rate and clinical benefit of these treatment regimens in these patients. IV. Compare Lung Cancer Symptom Scale scores, pulmonary function test scores, and lung density determinations with these treatment regimens in these patients. V. Compare toxicity of these treatment regimens in these patients. VI. Assess pharmacokinetics and vitamin metabolite status with these treatment regimens in these patients.

OUTLINE: This is a randomized, single blind, multicenter study. Patients are stratified according to performance status (Karnofsky 70-80% vs 90-100%), degree of measurability (bidimensional vs unidimensional only), histologic subtype (epithelial vs all others), WBC (8,300/mm3 and higher vs less than 8,300/mm3), pain intensity (low vs high), analgesic consumption (low vs high), dyspnea (low vs high), homocysteine (low vs high), gender, country, and treatment center. Patients are randomized to one of two treatment arms. Arm I: Patients receive LY231514 IV over 10 minutes followed by cisplatin IV over 2 hours on day 1. Arm II: Patients receive cisplatin as in arm I. Treatment repeats every 21 days for at least 6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed at 4 weeks, and then every 3 months thereafter.

PROJECTED ACCRUAL: A total of 280 patients (140 per treatment arm) will be accrued for this study within 15 months.
Frailty is a condition in which the affected individual is more prone to both external and internal stressors and has a higher risk of succumbing to chronic diseases. The aim of this research was to translate and validate the PRISMA-7 questionnaire in the Urdu language. This is a validation study conducted in a hospital in Khyber Pakhtunkhwa, Pakistan. PRISMA-7 Questionnaire was translated into Urdu language using forward and backward translations and was then piloted on a sample of 151 subjects, aged 60 and above, and validated by applying reliability and validity statistics. Amongst the sampling population, frailty was found to be 63.26%. All the items in the questionnaire were significantly different from each other, however, the correlation between each was found to be low. Cronbach's alpha was found to be 0.322. Urdu translated version of PRISMA-7 is not a valid and reliable tool for screening frailty in the elderly population of Khyber Pakhtunkhwa, Pakistan. Key Words: Frailty, Validation, Translation, Frail elderly, Urdu.
Procedure: open lung approach ventilation strategy (OLV). Patients receive volume-controlled mechanical ventilation with a tidal volume of 6 to 8 ml per kilogram of predicted body weight, a PEEP of 6 to 8 cm of water, and recruitment maneuvers repeated every 30 minutes after tracheal intubation.
PURPOSE:To reduce the working burden of an operator with a dental consultation job electronic computer by displaying a message for display of the insurance demand calculation and calculating the insurance demand when the artificial teeth are set or rebased. CONSTITUTION:The dental consultation is carried out to a patient and the consultation data on the various types of consultation are inputted through a keyboard 1 and stored in a consultation data file 5. At the same time, the data on various types of artificial teeth are stored in an oral control data file 6. When the based artificial teeth are set or rebased, a message is read out of the file 6 and displayed on a CRT display 7 for calculation of the insurance demand in response to a due treatment. Then a prescribed item is selected out of the message for calculation of the insurance demand of the treatment. Then a receipt is printed on a printing form 9 by a printer 8 in a dental insurance demand state.
1,274,797. Effervescent tablets and powders. BOEHRINGER MANNHEIM G.m.b.H. 11 Dec., 1970 [15 Dec., 1969], No. 58932/70. Heading A5B. [Also in Division C6] Effervescent tablets and powders which dissolve in water with the liberation of carbon dioxide comprise at least one alkali metal and/ or alkaline earth metal carbonate and/or bicarbonate and anhydrous sodium dihydrogen citrate, the tablets and powders being substantially free of citric acid and the di- and trisodium salts thereof. The tablets and powders may comprise sodium bicarbonate, potassium bicarbonate or calcium carbonate and additionally at least one water-soluble or suspendible pharmaceutical compound, such as vitamins (e.g. vitamin C), and analgesics (e.g. acetyl salicyclic acid), which can be administered orally. The effervescent tablets may be prepared by separately moist granulating the components, with the addition of a binding agent, drying and mixing the granulates obtained and then pressing into tablets, or by mixing together the finely powdered components with the addition of a lubricating agent such as polyethylene glycol, polyvinylpyrrolidone or gelatine, and then tabletting.
This invention provides a method for inducing weight loss in an animal by administering to the animal a compound which reduces the expression and/or secretion of neuropeptide Y (NPY). The effect may be accomplished directly, indirectly or humorally. Preferably, administration of this compound has the effect of increasing malonyl CoA levels in the animal. Compounds administered according to this invention may be inhibitors of fatty acid synthase (FAS), including substituted α-methylene-β-carboxyl-η-butyrolactones, or inhibitors of malonyl Coenzyme A decarboxylase (MCD). Preferably, the compound is administered in an amount sufficient to reduce the amount and/or duration of expression and/or secretion of NPY to levels at or below those observed for lean animals. In another preferred embodiment, the administration will reduce expression and/or secretion to levels observed for fed or satiated animals; more preferably, administration will reduce the level of NPY below that of fed animals. In a particular embodiment, this invention provides a method for inducing weight loss in an animal by administering a compound which inhibits feeding behavior in the animal. The method is particularly useful for inducing weight loss in animals deficient in expression of the hormone leptin or animals resistant to the action of leptin.
The present invention relates to regulatory sequences which mediate dendritic cell-specific expression. The regulatory sequences are isolated from the human fascin gene and also comprise for instance promoter sequences. Moreover, described are recombinant nucleic acid molecules and vectors which contain the regulatory sequences and as preferred embodiments, recombinant nucleic acid molecules and vectors encoding antigens or immunoregulatory proteins. Furthermore, the invention relates to host cells, which contain the recombinant nucleic acid molecules or vectors, and to methods for their preparation. Other embodiments relate to in vitro methods for stimulating T-cells and for preparing T cell-stimulating dendritic cells and for formulating them as pharmaceutical compositions. Additional pharmaceutical compositions are described which essentially relate to DNA vaccines and gene therapeutic pharmaceutical compositions, for instance for the immunization against and treatment of infectious diseases, tumors, allergies, Creutzfeldt-Jakob plaques or Alzheimer plaques. Additional pharmaceutical compositions according to the invention can be used for targeted, dendritic cell-mediated modulation of immune responses, for instance to treat autoimmune diseases or graft rejection. Moreover, various uses of the regulatory sequences are described.
A patient support system has a patient support surface 114 with one or more electronic display regions 301,302. One or more proximity sensors 218 indicate the presence of a person 304 or object 306 in the vicinity of the patient support surface and provide signals to a controller to control the information displayed based on the signals. Information may be displayed on the display region which is nearest to the detected person. The display may deactivate when nobody is present. The proximity sensors may identify an authorised person such that content relevant to that person is displayed; and/or the controller may be configured to display the next step in a clinical, service or physics workflow. The controller may also control an imaging apparatus, a radiotherapy apparatus and the patient support surface. The electronic display may include an input interface such as a touch screen, keyboard or microphone; it may be able to detect an alarm-indicating action by a patient.
Other tumors within 5 mm of the surface, whose planned treatment includes radiotherapy of the tumor and does not include a planned resection of the tumor. As these other qualifying malignancies are expected to occur only rarely, they will be grouped into a single cohort despite potential varied histology. These patients will receive a Carlo Erba Ink injection in their tumor prior to radiation therapy. All patients in this cohort will be expected to agree to a minimum of one EPR Oximetry measurement in the planned radiation field prior to radiation and a minimum of one measurement made over the course of radiation therapy.